Clinical Testing News and Research

RSS

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

16 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.

15 Nov 2010

Aeras receives grant to develop new vaccines for TB

The Aeras Global TB Vaccine Foundation is pleased to announce that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional 11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of tuberculosis.

12 Nov 2010

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.

11 Nov 2010

Deletion of 17q12 chromosomal region increases risk factor for ASD, schizophrenia

Researchers have identified the deletion of a genomic region on chromosome 17 as a significant risk factor for autism spectrum disorders (ASD) and schizophrenia. A mutation of one of the genes in the deleted interval already is a known cause of renal cysts and diabetes syndrome (RCAD).

8 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover's "Top 10 Cardiovascular/Metabolic Projects to Watch."

4 Nov 2010

InVivo receives $244,000 in grant funding under QTDP program

InVivo Therapeutics a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Tikcro Technologies Ltd. today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer.

3 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Trius receives patent protection for torezolid phosphate in the U.S.

Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).

26 Oct 2010

Wright Medical launches PRO-STIM Injectable Inductive Graft

Wright Medical Group, Inc. a global orthopaedic medical device company, is pleased to announce the full commercial launch of PRO-STIM Injectable Inductive Graft.

22 Oct 2010

Quest Diagnostics third quarter revenues decrease 1.7% to $1.9 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2010, income from continuing operations increased to $198 million, or $1.13 per diluted share, from $192 million, or $1.02 per diluted share, for the third quarter of 2009.

From Quest Diagnostics 20 Oct 2010

FDA grants fast track designation for Aastrom's CLI cell therapy development program

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted fast track designation for the company's critical limb ischemia (CLI) cell therapy development program. Aastrom plans to initiate Phase 3 clinical testing of its treatment for CLI in early 2011.

18 Oct 2010

IDRI's TB vaccine protects against drug-resistant tuberculosis

The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies are published in Science Translational Medicine today.

18 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Clinical Testing News and Research

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

Adeona third quarter total net revenues increase to $289,898

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Aeras receives grant to develop new vaccines for TB

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

Deletion of 17q12 chromosomal region increases risk factor for ASD, schizophrenia

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

InVivo receives $244,000 in grant funding under QTDP program

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

ImmunoGen first quarter net loss increases to $12.9 million

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Trius receives patent protection for torezolid phosphate in the U.S.

Wright Medical launches PRO-STIM Injectable Inductive Graft

Quest Diagnostics third quarter revenues decrease 1.7% to $1.9 billion

FDA grants fast track designation for Aastrom's CLI cell therapy development program

IDRI's TB vaccine protects against drug-resistant tuberculosis

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News